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671Abstracts
the incremental-cost-per-life-year-saved of tenecteplase
over alteplase is about €3600, and for that reason it
should be preferred on the basis of its very cost-effective
ratio. For patients at the age of 62, for whom treatment
starts late the average cost and survival was €23.671,
€23.304, €24.343, and 7.9172, 7.7716, and 8.2093
respectively. The incremental cost of tenecteplase was
lower this time at €2.305. These results are based the
point estimates and in general terms they also hold true
when simulation is employed. CONCLUSIONS: The
treatments evaluated here are similar in respect of total
treatment costs, so that it is difﬁcult to distinguish
between them. If anything, tenecteplase is characterized
by a marginally better cost-effectiveness ratio.
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OBJECTIVE: To examine the cost-effectiveness (CE) of
atorvastatin compared to simvastatin in the treatment 
of patients with dyslipidemia in the Netherlands.
METHODS: The cost-effectiveness was evaluated using
effectiveness data from the LIZO trial, a 3-month clini-
cal trial in which patients were compared on milligram-
equivalent doses of either 20 or 40mg atorvastatin or
simvastatin. Short-term (three month) cost-effectiveness
was assessed based on the percentage of patients reach-
ing EAS or NCEP ATP-II LDL treatment targets, and drug
cost. These results were extrapolated to a 10-year period.
This long-term CE-evaluation assessed drug costs, CHD-
event costs, and life years gained. Patients reaching target
cholesterol levels and remaining on drug treatment were
assumed to have a maximum reduction in risk of CHD
events during the 10-year period; patients not reaching
target levels were assumed to have an average risk reduc-
tion for CHD-events. Risk calculation for CHD-events
was based on Dutch CBO-guidelines. Cardiac events were
assumed to occur after 5 years. One- and two-way sensi-
tivity analyses were performed. RESULTS: Short-term
cost-effectiveness analyses showed cost-effectiveness
between €51 and €422 per successfully treated patient.
The results of the long-term analyses indicated dominance
of the atorvastatin treatment in the 20mg group using
both EAS and NCEP-guidelines. For patients treated with
40mg, dominance was observed using NCEP-guidelines
and cost-effectiveness of €7,889 per life-year gained using
the EAS-guidelines. In the sensitivity analyses the results
were robust and below the €18,000 benchmark stated in
the Dutch guidelines, with the exception of time of occur-
rence of CHD events. CONCLUSION: This CE-analysis
regarding dyslipidemia treatment is the ﬁrst evaluation
conducted in the last 10 years in the Netherlands. The
study showed low cost-effectiveness for the short-term
evaluation and cost-savings for atorvastatin in compari-
son to simvastatin in 3 of the 4 evaluations in the long-
term CE-analyses.
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OBJECTIVES: Few measures are available for use in pul-
monary hypertension (PH), limiting outcome assessment
in this condition. Generic outcome measures are of
limited value due to their lack of PH-speciﬁcity. Two new
PH-speciﬁc instruments were developed; a HRQL (health
status) and a QoL measure. METHODS: Patients were
recruited from Papworth Hospital in the UK for unstruc-
tured interviews. Comments from patients were used to
create item pools for a HRQL and QoL measure. The
HRQL measure focuses on impairments (symptoms) and
disability (functioning) while the QoL measure focuses on
the impact of PH on patients’ abilities to meet their needs.
The measures were included in a postal survey. Rasch
analysis was used to reduce items and conﬁrm unidimen-
sionality of scales. Revised measures were then ﬁeld-
tested with PH patients. RESULTS: Thirty-ﬁve patients
were interviewed (M:F = 9:26). Ages ranged from 20–
80yrs (mean = 50yrs). Content analysis indicated a wide
impact of PH on HRQL and QoL. Seventy-nine patients
completed the postal survey (M:F = 20:54); age range
19–81yrs (mean = 52yrs). Rasch analyses showed all
scales (including the overall impairment scale and its sub-
scales: Breathlessness, Oedema, Energy, and Mood) ﬁtted
the model after deleting mis-ﬁtting items. All scales exhib-
ited good severity coverage and internal consistency
(Alpha); impairment = 0.79; disability = 0.93; QoL =
0.93. The 41-item impairment scale, 17-item functioning
scale, and 36-item QoL scale were ﬁeld-tested with 15
patients (M:F = 5:10); age range 25–72yrs (mean =
52yrs). Measures were found to be relevant, comprehen-
sible, and quick to complete (completion time range = 4–5
minutes). CONCLUSIONS: The new PH measures were
well-accepted by respondents who consider their content
comprehensive and relevant. A second postal survey is
under way to enable psychometric testing of the mea-
sures. The ﬁnal measures will be invaluable for outcome
assessment of PH patients.
